Amphastar Pharmaceuticals Inc. Common Stock (AMPH)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for a margin of safety and a business that earns more than its cost of capital. Amphastar makes specialty injectable, inhalation, and intranasal drugs, a niche with regulatory barriers but also generic price pressure. In fiscal 2025, the year ended 2025-12-31, revenue was $719.9M and net income was $98.1M, or diluted EPS of $2.03. That was down from fiscal 2024, the year ended 2024-12-31, when revenue was $732.0M, net income $159.5M, and diluted EPS $3.06. FairStock's Lynch category is FAST GROWER, but the latest annual profit trend is weak. More recent quarters are volatile: in fiscal Q1 2026, the quarter ended 2026-03-31, net income was only $6.4M, while in fiscal Q2 2026, the quarter ended 2026-06-30, net income was $30.3M and diluted EPS $0.67.

In plain English: Amphastar makes specialty generic and branded medicines, mostly injectable, inhaled, and nasal products such as emergency glucagon and asthma treatments. The company generates solid cash and carries a reasonable price relative to profits, but recent annual profit fell and the balance sheet has some debt. At $26.05, the shares look close to fair value rather than clearly cheap or expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer